← Leaderboards
David T. Teachey
Children'S Hosp Of Philadelphia
$3,927,557
Attributed
$9,680,963
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,680,963 · 5
By mechanism
R01$8,403,832 · 2
R21$462,821 · 1
R56$432,341 · 1
R03$381,969 · 1
Top collaborators
- Michelle L Hermiston8 shared
- Terzah M Horton8 shared
- Brent L Wood8 shared
- Jun J. Yang5 shared
- Charles G. Mullighan1 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Craig H. Bassing$11,972,566
- Sarah Kathleen Tasian$5,299,505
- Evan William Weber$3,427,998
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildRelapseBiologyCellsResponseHigh RiskResistanceClinical TrialsPediatric Oncology GroupAcute T Cell LeukemiaChemotherapyNovel TherapeuticsCytotoxic ChemotherapySignal TransductionSignal PathwayPathway InteractionsHeterogeneityReportingPhenotypeCohortGenomicsGenesInnovationSurvival Rate
Grant awards (17)
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$737,926
R01 · FY2025 · CA · contact PI
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia$599,172
R01 · FY2025 · CA
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$721,069
R01 · FY2024 · CA · contact PI
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia$569,213
R01 · FY2024 · CA
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$851,561
R01 · FY2023 · CA · contact PI
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia$587,189
R01 · FY2023 · CA
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia$587,189
R01 · FY2022 · CA
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia$619,047
R01 · FY2021 · CA
Genomic Profiling of T-cell Acute Lymphoblastic Leukemia in Children$381,969
R03 · FY2021 · CA · contact PI
Improving risk allocation and developing novel therapies for children with T-ALL$575,456
R01 · FY2019 · CA · contact PI
Improving risk allocation and developing novel therapies for children with T-ALL$594,741
R01 · FY2018 · CA · contact PI
Improving risk allocation and developing novel therapies for children with T-ALL$625,779
R01 · FY2017 · CA · contact PI
Improving risk allocation and developing novel therapies for children with T-ALL$626,176
R01 · FY2016 · CA · contact PI
Improving risk allocation and developing novel therapies for children with T-ALL$709,314
R01 · FY2015 · CA · contact PI
Targeting Akt signaling in Autoimmune Lymphoproliferative Syndrome$197,833
R21 · FY2013 · AI · contact PI
Targeting Akt signaling in Autoimmune Lymphoproliferative Syndrome$264,988
R21 · FY2012 · AI · contact PI
Targeting the mTOR signaling pathway in Autoimmune Lymphoproliferative Syndrome$432,341
R56 · FY2011 · AI · contact PI